June 2009 Volume 23 Number 6, pp 1019 - 1206
----------------------------------------------------------------------
>>BD Biosciences
BD offers medical supplies, devices, laboratory equipment and diagnost
ic products including antibodies and reagents for flow cytometry, west
ern blotting, immunofluorescence, and ELISA. Instruments include bioim
agers, flow cytometers, and cell sorters for research and clinical app
lications.
Please visit
http://links.ealert.nature.com/ctt?kn=37&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
for more information.
----------------------------------------------------------------------
Leukemia - celebrating over 20 years of distinguished research!
2007 marked Leukemia's 20th year in providing the science community
with the most crucial research and advances in leukemia and
allied diseases. Throughout 2007 Leukemia offered special
promotions, including FREE access to selected articles from current
and past issues. Visit Leukemia online at
http://links.ealert.nature.com/ctt?kn=5&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
to learn about upcoming promotions!
----------------------------------------------------------------------
Why Publish in Leukemia?
Efficient peer-review, hassle-free submission, recognition...
Papers benefit from wide readership through hosting on nature.com and
inclusion in the leading abstracting and indexing services.
Rapid publication is also assured through Advance Online Publication.
To read the full Guide to Authors for Leukemia, visit
http://links.ealert.nature.com/ctt?kn=103&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
----------------------
ORIGINAL ARTICLES
----------------------
The DNA methyltransferase inhibitors azacitidine, decitabine and
zebularine exert differential effects on cancer gene expression in
acute myeloid leukemia cells
C Flotho, R Claus, C Batz, M Schneider, I Sandrock, S Ihde, C Plass,
C M Niemeyer and M Lubbert
Abstract: http://links.ealert.nature.com/ctt?kn=4&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=55&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
The level of AKT phosphorylation on threonine 308 but not on serine
473 is associated with high-risk cytogenetics and predicts poor
overall survival in acute myeloid leukaemia
N Gallay, C Dos Santos, L Cuzin, M Bousquet, V Simmonet Gouy,
C Chaussade, M Attal, B Payrastre, C Demur and C Recher
Abstract: http://links.ealert.nature.com/ctt?kn=17&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=115&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Vasculogenic mimicry of acute leukemic bone marrow stromal cells
P Mirshahi, A Rafii, L Vincent, A Berthaut, R Varin, G Kalantar,
C Marzac, O A Calandini, J-P Marie, C Soria, J Soria and M Mirshahi
Abstract: http://links.ealert.nature.com/ctt?kn=57&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=44&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Loss of RAF kinase inhibitor protein is a somatic event in the
pathogenesis of therapy-related acute myeloid leukemias with
C-RAF germline mutations
A Zebisch, M Haller, K Hiden, T Goebel, G Hoefler, J Troppmair
and H Sill
Abstract: http://links.ealert.nature.com/ctt?kn=67&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=73&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Six-year follow-up of patients receiving imatinib for the
first-line treatment of chronic myeloid leukemia
A Hochhaus, S G O'Brien, F Guilhot, B J Druker, S Branford,
L Foroni, J M Goldman, M C Muller, J P Radich, M Rudoltz, M Mone,
I Gathmann, T P Hughes and R A Larson
Abstract: http://links.ealert.nature.com/ctt?kn=8&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=24&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Telomere length is an independent predictor of survival,
treatment requirement and Richter's syndrome transformation
in chronic lymphocytic leukemia
D Rossi, C Lobetti Bodoni, E Genuardi, L Monitillo, D Drandi,
M Cerri, C Deambrogi, I Ricca, A Rocci, S Ferrero, E Bernocco,
D Capello, L De Paoli, L Bergui, M Boi, P Omede, M Massaia,
C Tarella, R Passera, M Boccadoro, G Gaidano and M Ladetto
Abstract: http://links.ealert.nature.com/ctt?kn=124&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=6&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Prognostic significance of minimal residual disease in infants
with acute lymphoblastic leukemia treated within the
Interfant-99 protocol
V H J Van der Velden, L Corral, M G Valsecchi, M W J C Jansen,
P De Lorenzo, G Cazzaniga, E R Panzer-Grumayer, M Schrappe,
A Schrauder, C Meyer, R Marschalek, L L Nigro, M Metzler,
G Basso, G Mann, M L Den Boer, A Biondi, R Pieters and
J J M Van Dongen
Abstract: http://links.ealert.nature.com/ctt?kn=14&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=9&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Caspase activation is involved in early megakaryocyte
differentiation but not in platelet production from
megakaryocytes
Y Kozuma, S Yuki, H Ninomiya, T Nagasawa and H Kojima
Abstract: http://links.ealert.nature.com/ctt?kn=22&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=26&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Antiepileptic drugs reduce efficacy of methotrexate
chemotherapy by downregulation of Reduced folate carrier
transport activity
S Halwachs, I Schafer, P Seibel and W Honscha
Abstract: http://links.ealert.nature.com/ctt?kn=98&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=53&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Characterization of the ubiquitin-proteasome system in
bortezomib-adapted cells
T Ruckrich, M Kraus, J Gogel, A Beck, H Ovaa, M Verdoes,
H S Overkleeft, H Kalbacher and C Driessen
Abstract: http://links.ealert.nature.com/ctt?kn=74&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=123&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Flow cytometric immunobead assay for the detection of
BCR-ABL fusion proteins in leukemia patients
F Weerkamp, E Dekking, Y Y Ng, V H J van der Velden,
H Wai, S Bottcher, M Bruggemann, A J van der Sluijs,
A Koning, N Boeckx, N Van Poecke, P Lucio, A Mendonca,
L Sedek, T Szczepanski, T Kalina, M Kovac, P G Hoogeveen,
J Flores-Montero, A Orfao, E Macintyre, L Lhermitte,
R Chen, K A J Brouwer-De Cock, A van der Linden,
A L Noordijk, W M Comans-Bitter, F J T Staal and
J J M van Dongen
Abstract: http://links.ealert.nature.com/ctt?kn=10&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=46&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Analysis of the host pharmacogenetic background for
prediction of outcome and toxicity in diffuse large
B-cell lymphoma treated with R-CHOP21
D Rossi, S Rasi, S Franceschetti, D Capello, A Castelli,
L De Paoli, A Ramponi, A Chiappella, E M Pogliani,
U Vitolo, I Kwee, F Bertoni, A Conconi and G Gaidano
Abstract: http://links.ealert.nature.com/ctt?kn=27&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=45&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Effective treatment of advanced-stage childhood
lymphoblastic lymphoma without prophylactic cranial
irradiation: results of St Jude NHL13 study
J T Sandlund, C-H Pui, Y Zhou, F G Behm, M Onciu,
B I Razzouk, N Hijiya, D Campana, M M Hudson and
R C Ribeiro
Abstract: http://links.ealert.nature.com/ctt?kn=97&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=77&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
The hematopoietic cell transplantation comorbidity
index (HCT-CI) predicts clinical outcomes in
lymphoma and myeloma patients after reduced-intensity
or non-myeloablative allogeneic stem cell
transplantation
L Farina, B Bruno, F Patriarca, F Spina, R Sorasio,
M Morelli, R Fanin, M Boccadoro and P Corradini
Abstract: http://links.ealert.nature.com/ctt?kn=65&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=100&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Genomic analyses reveal global functional alterations
that promote tumor growth and novel tumor suppressor
genes in natural killer-cell malignancies
J Iqbal, C Kucuk, R J deLeeuw, G Srivastava, W Tam,
H Geng, D Klinkebiel, J K Christman, K Patel, K Cao,
L Shen, K Dybkaer, I F L Tsui, H Ali, N Shimizu,
W Y Au, W L Lam and W C Chan
Abstract: http://links.ealert.nature.com/ctt?kn=106&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=23&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Improved survival of patients with multiple myeloma
after the introduction of novel agents and the
applicability of the International Staging
System (ISS): an analysis of the Greek Myeloma
Study Group (GMSG)
E Kastritis, K Zervas, A Symeonidis, E Terpos,
S Delimbassi, N Anagnostopoulos, E Michali, A Zomas,
E Katodritou, D Gika, A Pouli, D Christoulas,
M Roussou, Z Kartasis, T Economopoulos and
M A Dimopoulos
Abstract: http://links.ealert.nature.com/ctt?kn=33&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=58&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
----------------------
LETTERS TO THE EDITOR
----------------------
Sustained major molecular response in the absence
of any antileukaemic therapy after dasatinib
treatment and autologous peripheral blood stem
cell transplantation in a patient with imatinib-resistant
myeloblastic-phase chronic myeloid leukaemia
D Rea, E Raffoux, J-M Cayuela, O Maarek and H Dombret
http://links.ealert.nature.com/ctt?kn=3&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
miR-34a, miR-29c and miR-17-5p are downregulated in
CLL patients with TP53 abnormalities
M Mraz, K Malinova, J Kotaskova, S Pavlova, B Tichy,
J Malcikova, K Stano Kozubik, J Smardova, Y Brychtova,
M Doubek, M Trbusek, J Mayer and S Pospisilova
http://links.ealert.nature.com/ctt?kn=110&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Therapy-related acute myeloid leukaemia with t(8;16)
(p11;p13);MOZ-CBP and polymorphisms in detoxifying
and DNA repair genes
E M Boyd, A J Bench, K J Vaghela, G N Campbell,
F B Chowdhury, E J Gudgin, M A Scott and W N Erber
http://links.ealert.nature.com/ctt?kn=34&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Depletion of L-asparagine supply and apoptosis of
leukemia cells induced by human glycosylasparaginase
E Kelo, T Noronkoski and I Mononen
http://links.ealert.nature.com/ctt?kn=62&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Reduced-intensity allogeneic transplantation combined
with imatinib mesylate for chronic myeloid
leukemia in first chronic phase
Y Luo, X-Y Lai, Y-M Tan, J-M Shi, Y-M Zhao, X-Y Han,
G-F Zheng, X-L Zhu, J Sun, Y-L Zheng, G-Q Wu,
J-S He, S-Y Chen, A-Y Jin, W-Z Xie, X-J Ye, Z Cai,
M-F Lin and H Huang
http://links.ealert.nature.com/ctt?kn=12&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Hypermethylation of Death-Associated Protein Kinase
1 differentiates natural killer cell lines from
cell lines derived from T-acute lymphoblastic leukemia
S Rohrs, J Romani, M Zaborski, H G Drexler and
H Quentmeier
http://links.ealert.nature.com/ctt?kn=50&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
In situ localization of follicular lymphoma: evidence
for subclinical systemic disease with detection of
an identical BCL-2/IGH fusion gene in blood
and lymph node
M C Cheung, D Bailey, N Pennell, K R Imrie,
N L Berinstein, D Amato and Z Ghorab
http://links.ealert.nature.com/ctt?kn=38&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Ectopic expression of the HLXB9 gene is associated
with an altered nuclear position in t(7;12) leukaemias
E Ballabio, C D Cantarella, C Federico, P Di Mare,
G Hall, J Harbott, J Hughes, S Saccone and S Tosi
http://links.ealert.nature.com/ctt?kn=101&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
The CLLU1 expression level is a stable and inherent
feature of the chronic lymphocytic leukemia clone
A M Buhl, G W Novotny, P Josefsson, J E Nielsen,
L B Pedersen, C Geisler, L Z Rassenti, T J Kipps,
J Jurlander and H Leffers
http://links.ealert.nature.com/ctt?kn=121&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
SOCS3 inhibits TPO-stimulated, but not spontaneous,
megakaryocytic growth in primary myelofibrosis
R Chaligne, C Tonetti, R Besancenot, C Marty,
J-J Kiladjian, G Socie, D Bordessoule, W Vainchenker
and S Giraudier
http://links.ealert.nature.com/ctt?kn=93&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
t(11;14)-positive clones can persist over a
long period of time in the peripheral blood of
healthy individuals
Y Lecluse, P Lebailly, S Roulland, A-C Gac,
B Nadel and P Gauduchon
http://links.ealert.nature.com/ctt?kn=60&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Imatinib dose escalation for chronic phase-chronic
myelogenous leukaemia patients in primary
suboptimal response to imatinib 400[thinsp]mg
daily standard therapy
D Rea, G Etienne, S Corm, P Cony-Makhoul,
M Gardembas, L Legros, V Dubruille, S Hayette,
F-X Mahon, J-M Cayuela and F E Nicolini
http://links.ealert.nature.com/ctt?kn=72&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Genes encoding multiple forms of phospholipase A2
are expressed in immature forms of human leukemic
blasts
R Fiancette, C Vincent, M Donnard, D Bordessoule,
P Turlure, F Trimoreau and Y Denizot
http://links.ealert.nature.com/ctt?kn=86&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
A pilot study of continuous imatinib vs pulsed
imatinib with or without G-CSF in CML patients
who have achieved a complete cytogenetic response
M W Drummond, N Heaney, J Kaeda, F E Nicolini,
R E Clark, G Wilson, P Shepherd, J Tighe, L McLintock,
T Hughes and T L Holyoake
http://links.ealert.nature.com/ctt?kn=102&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Translocation t(14;18) is not associated with inferior
outcome in chronic lymphocytic leukemia
N Put, P Meeus, B Chatelain, K Rack, N Boeckx,
F Nollet, C Graux, E Van Den Neste, A Janssens,
V Madoe, A Van Hoof, C Bilhou-Nabera, I Wlodarska,
P Vandenberghe and L Michaux
http://links.ealert.nature.com/ctt?kn=28&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
Short-term intense Bcr-Abl kinase inhibition with
nilotinib is adequate to trigger cell death
in BCR-ABL+ cells
D K Hiwase, D L White, V A Saunders, S Kumar,
J V Melo and T P Hughes
http://links.ealert.nature.com/ctt?kn=13&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
----------------------------------------------------------------------
Ensure your access
If you are unable to access the articles in this Table of Contents
e-alert, your library may not subscribe to this journal.
Our online recommendation form is a simple way to make your
librarian aware that this journal is valuable to your research.
Recommend now at
http://links.ealert.nature.com/ctt?kn=32&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
=====================================================================
You have been sent this Table of Contents Alert because you have opted in to receive it.
You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=16&m=33396174&r=MTc2MzIyNTA1NQS2&b=2&j=NTExODgwMzkS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne - San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
© Copyright 2009 Nature Publishing Group
=====================================================================
